Salix Pharmaceuticals, Ltd. company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.

Fornix was established in 1999 after a reverse takeover of Dr. Fisher Farma B.V. by Artu Biologicals. Fornix BioSciences has joined the draft in the war against allergies. The Dutch company develops diagnostic and immunotherapeutic allergen products and medical aids. Its allergy division develops and markets sublingual (under the tongue) allergen aids to human and animal patients, particularly dogs, throughout Europe. The company's trading division, Dr. Fisher Farma, imports and distributes a variety of patented drugs, while its Medical Aids division focuses on the sale of medical aids and medical and nursing disposables.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Catalent Pharma Solutions, Inc. provides proprietary drug delivery and packaging technologies, and outsourced services to pharmaceutical, biotechnology, and consumer healthcare companies worldwide. It operates in three segments: Oral Technologies, Sterile Technologies, and Packaging Services. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products, which are used in various customer products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as tablets and capsules. The Sterile Technologies segment produces various sterile dose forms used in the prescription drug and biologic market.This segment provides formulation and development for injectables, as well as lyophilization for otherwise unstable drugs and biologics. It also fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats; and offers blow-fill-seal technology. In addition, this segment offers biologic cell line development, analytical, and scientific consulting services, as well as provides services for inhaled products. The Packaging Services segment provides various contract packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit-doses; printed components services, such as creating package inserts or folding cartons; and clinical trial supply services providing packaging, and inventory and logistics management for clinical trials. The company has a strategic alliance with Endotis Pharma to develop oral formulations of synthetic oligosaccharides. The company is based in Somerset, New Jersey.

Intercell AG really wants give the pharmaceutical industry a shot in the arm. The Austrian company develops new vaccinations that aim to invoke strong immune system responses. It sells a travelers vaccine for Japanese encephalitis in areas of Europe, the Asia/Pacific region, and North America. Vaccine development candidates aim to fight staph infections, pandemic influenza, hepatitis C, and other viral and bacterial infections. The company also develops antibody (protein) therapies. Intercell has commercial licensing and co-development agreements with larger companies, including Novartis, Sanofi-Aventis, and Merck.

AVAX Technologies company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor® (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast to higher-dose doxepin, Silenor is a potent antagonist that appears to selectively block histamine at the H1 receptor without a clinically relevant impact on other neurotransmitter systems. Doxepin at higher doses has been associated with a range of pharmacologic side effects that include anticholenerigic effects (dry mouth, constipation, etc.) and weight gain. In clinical trials, patients taking Silenor generally did not exhibit the side effects associated with higher doses of doxepin.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

VIVUS, Inc. company was founded in 1991 and is headquartered in Mountain View, California. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the Phase III studies are in process and one Phase III study has been completed; Qnexa for treating diabetes, for which a one-year Phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction; for which Phase III studies are in process, and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.